Quarterly Journal of Science and Practice
E. F. Cherednikov, I. S. Yuzefovich, S. V. Barannikov, I. N. Banin, A. V. Chernykh, G. G. Rostiashvili, A. E. Bolkhovitinov, I. A. Shkurina
Воронежский государственный медицинский университет имени Н. Н. Бурденко, Воронеж, Россия; Воронежская городская клиническая больница скорой медицинской помощи № 1, Воронеж, Россия; ООО «НКФ Омега-Дент», Воронеж, Россия
The aim of the study was to develop and apply in clinical practice a method of endoscopic treatment of bleed- ing ruptures using Algistab hemostatic in patients with Mallory – Weiss syndrome (MWS). Material and methods. The clin- ical study included 121 patients with MWS. 65 patients made up the main group (MG). They used endoscopic insufflations of the powdered hemostatic Algistab to treat bleeding ruptures. In the control group (CG) in 56 patients, endohemostasis was performed by injection methods, diathermocoagulation, argonoplasmic coagulation (APC), etc. without hemostatic. Results. Final hemostasis in the MG was achieved in 96.9 % of patients, bleeding resumed in 2 (3.1 %) of 65 patients. There were no operations in the MG, no one died. In CG, the final stop of bleeding was 85.7 %, recurrence of hemorrhage was noted in 8 (14.3 %) patients out of 56. In this group, 2 (3.6 %) patients died without surgery. Conclusion. The devel- oped method of endoscopic treatment of MWS using cytoprotective technologies enhances the hemostatic effect, reduces the number of recurrent hemorrhages, promotes the process of epithelization of defects in 92.3 % of cases (p = 0.0001), accelerates the healing time of defects from 10.0 (5.0–12.0) to 5.0 (4.0–6.0) days (p = 0.0001).
Mallory – Weiss syndrome, endoscopic hemostasis, cytoprotective treatment
Show full text of article